CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.


Frontline Axi-Cel Elicits Durable Responses in High-Risk LBCL

December 14th 2021

Frontline treatment with axicabtagene ciloleucel demonstrated rapid and durable responses in patients with high-risk large B-cell lymphoma.

Cilta-Cel Continues to Impress With Durable and Deep Responses in Relapsed/Refractory Multiple Myeloma

December 13th 2021

Ciltacabtagene autoleucel elicited a 97.9% objective response rate and an 82.5% stringent complete response rate in patients with relapsed/refractory multiple myeloma at a median of approximately 2 years of follow-up.

Shah and Wang Share Insights Into Optimized CAR T-Cell Therapy in Hematologic Malignancies

December 13th 2021

Dr. Shah and Dr. Wang discuss the management of cytokine release syndrome and neurotoxicity, the referral process, and the need for academic and community collaboration for CAR T-cell therapy in hematologic malignancies.

Axi-Cel Improves QoL in Second-Line Treatment of LBCL

December 12th 2021

Axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell therapy, resulted in clinically meaningful improvement in quality of life at day 100 compared with standard of care as a second-line treatment of patients with relapsed/refractory large B-cell lymphoma.

Tisagenlecleucel Continues to Show Favorable Real-World Efficacy and Safety in R/R B-Cell Non-Hodgkin Lymphomas

December 12th 2021

Tisagenlecleucel demonstrated encouraging real-world efficacy and a favorable safety profile that was consistent with findings from the pivotal phase 2 JULIET trial in patients with relapsed/refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma.

Brexucabtagene Autoleucel Expands Treatment Possibilities in ALL

December 3rd 2021

Bijal Shah, MD, MS, discussed the results of the ZUMA-3 trial and how this approval will enhance the treatment of patients with relapsed or refractory B-cell precursor ALL.

Lisocabtagene Maraleucel Displays Durable Remissions in Relapsed/Refractory LBCL

November 29th 2021

Lisocabtagene maraleucel demonstrated durable responses and a favorable safety profile in patients with relapsed/refractory large B-cell lymphoma.

Dr. Shah and Dr. Wang on the Need for Academic and Community Collaboration With CAR T-Cell Therapy

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.

Dr. Shah and Dr. Wang on the Challenges of Managing High-Risk MCL

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the challenges of managing high-risk mantle cell lymphoma.

Dr. Shah and Dr. Wang on Navigating the Referral Process for CAR T-Cell Therapy in Hematologic Malignancies

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss navigating the referral process for CAR T-cell therapy in hematologic malignancies.

Dr. Shah and Dr. Wang on Managing CRS and Neurotoxicity in Leukemia/Lymphoma

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss management strategies for CAR T-cell therapy–related cytokine release syndrome and neurotoxicity in leukemia and lymphoma.

Dr. Shah and Dr. Wang on CAR T-Cell Therapy–Associated Toxicities in Hematologic Malignancies

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the main CAR T-cell therapy–associated toxicities in hematologic malignancies.

FDA Grants RMAT Designation to CTX110 for Relapsed/Refractory CD19+ B-Cell Malignancies

November 23rd 2021

he FDA has granted a Regenerative Medicine Advanced Therapy designation to the allogeneic CAR T-cell therapy CTX110 for the treatment of patients with relapsed or refractory, CD19-positive B-cell malignancies.

Dr. Reiss Binder on Initial Results of a Phase 1 Study of CT-0508 in HER2+ Solid Tumors

November 23rd 2021

Kim A. Reiss Binder, MD, discusses the initial results of a phase 1 trial, which is evaluating CT-0508 in patients with HER2-overexpressing solid tumors.

Efforts Needed to Evaluate How CAR T-Cell Therapy Recipients Respond to COVID-19 Vaccination

November 22nd 2021

Muhammad Bilal Abid, MD, discusses immune-compromising factors that are indigenous to CAR T-cell recipients, the immunogenic potential of different COVID-19 vaccines, determinants of response, and the potential need for booster strategies.

Celularity and Imugene Enter into Potentially ‘Game-Changing’ Collaboration

November 18th 2021

Chimeric antigen receptor T-cell therapies are rapidly shifting the treatment paradigm for a multitude of hematologic malignancies.

Therapeutic Frontiers for Relapsed/Refractory Multiple Myeloma Expand With CAR T and Bispecific Antibodies

November 5th 2021

CAR T-cell therapy and bispecific antibodies for T-cell redirection are 2 recent immune strategies developed in the treatment of multiple melanoma.

Treatment Sequencing Could Change With Complementary Combinations and CAR T Options in B-ALL

November 5th 2021

Significant progress with rapidly evolving therapies, including blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy, has been made to extend the median overall survival and improve outcomes for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Bispecific Monoclonal Antibodies Lead Immune-Directed Therapies into the Future

November 4th 2021

Increases investigative efforts into bispecific monoclonal antibodies could lead to their availability to treat a broad range of hematologic and solid cancers. Their current use in practice is limited to non–small cell lung cancer, leukemia, and hemophilia.

FDA Extends Decision Date for Cilta-Cel BLA in Relapsed/Refractory Multiple Myeloma

November 2nd 2021

The FDA has extended the Prescription Drug User Fee Act target date for the biologics license application seeking the approval of the CAR T-cell therapy ciltacabtagene autoleucel for use in adult patients with relapsed and/or refractory multiple myeloma.